Accès ouvert
2025
article
OpenAlex
Lauren Edwards, Amanda Gonzalez, Kelsey R. Thomas, Denis Smirnov et autres
INTRODUCTION: Some research suggests that blood-brain barrier (BBB) integrity is altered in Alzheimer's disease (AD). Few studies have examined markers of BBB integrity and their interactions with AD risk factors on multi-domain cognition. METHODS: 83 older adults without dementia underwent lumbar puncture, …
us, se
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Lauren Edwards, Denis S. Smirnov, Kelsey R. Thomas, Katherine Longardner et autres
INTRODUCTION: Among individuals who are amyloid biomarker-positive or apolipoprotein E (APOE) ε4 carriers, arterial stiffness reflected by higher pulse wave velocity (PWV) has been associated with lower cognition cross-sectionally. Less is known about longitudinal associations. METHODS: The sample included 152 older adults …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Raeanne C Moore, Shay Nakahira, Linda C. Gallo, Alexander P. Demos et autres
Objective: Hispanic/Latino/a/x (hereafter Latino) persons living in the U.S. are at increased risk for Alzheimer's disease and related dementias (ADRD) compared to non-Latino Whites. Early detection of preclinical changes is crucial. The SALUD-Tech study aims to identify digital behavioral markers-"digital signatures"-of ADRD …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jon B. Toledo, David P. Salmon, Melissa J. Armstrong, Douglas Galasko
BACKGROUND: Alzheimer's disease neuropathologic change (ADNC) and Lewy pathology (LP) often coexist in cognitively impaired individuals. These pathologies' relative distribution and severity may modify these individuals' clinical presentation, cognitive profile, and prognosis. Therefore, we examined the contributions of LP and concomitant ADNC …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Daniel Weintraub, Ryan Kurth, Michael C. Brumm, Michele K. York et autres
Objectives: To determine the impact of dopamine deficiency and isolated REM sleep behavior disorder (iRBD) on cognitive performance in early neuronal alpha-synuclein disease (NSD) with hyposmia. Methods: Using Parkinson's Progression Markers Initiative baseline data, cognitive performance was assessed with a cognitive summary …
us, de, il
(code pays fourni par la source)
2024
book-chapter
OpenAlex
Howard Feldman, Karen Messer, Yuqi Qiu, Marwan Sabbagh et autres
Background: Varoglutamstat is a first-in-class, small molecule being investigated as a treatment for early Alzheimer’s disease (AD). It is an inhibitor of glutaminyl cyclase (QC), the enzyme that post-translationally modifies amyloid-β (Aβ) peptides into a toxic form of pyroglutamate Aβ (pGlu-Aβ) and …
us, cn, ca
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Howard Feldman, Karen Messer, Yuqi Qiu, Marwan Sabbagh et autres
Background: Varoglutamstat is a first-in-class, small molecule being investigated as a treatment for early Alzheimer's disease (AD). It is an inhibitor of glutaminyl cyclase (QC), the enzyme that post-translationally modifies amyloid-β (Aβ) peptides into a toxic form of pyroglutamate Aβ (pGlu-Aβ) and …
us, cn, ca
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig et autres
Abstract Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-responsive element in APP mRNA and decreases …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Dean Ornish, Catherine Madison, Miia Kivipelto, Colleen Kemp et autres
BACKGROUND: Evidence links lifestyle factors with Alzheimer's disease (AD). We report the first randomized, controlled clinical trial to determine if intensive lifestyle changes may beneficially affect the progression of mild cognitive impairment (MCI) or early dementia due to AD. METHODS: A 1:1 …
us, se, fi, gb
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig et autres
ABSTRACT Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen binds to an iron-responsive element in APP mRNA and decreases translation of APP and Aβ. …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jonathan E. Elliott, Brittany R. Ligman, Mohini Bryant‐Ekstrand, Allison Keil et autres
STUDY OBJECTIVES: Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson's disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)-henceforth "neurotrauma" (NT)-increase the odds …
us, ca
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jonathan E. Elliott, Mohini Bryant‐Ekstrand, Allison Keil, Brittany R. Ligman et autres
BACKGROUND AND OBJECTIVES: Although orthostatic hypotension (OH) can be an early feature of autonomic dysfunction in isolated REM sleep behavior disorder (iRBD), no large-scale studies have examined the frequency of OH in iRBD. In this study, we prospectively evaluated the frequency of …
us
(code pays fourni par la source)